Condition: Neuroendocrine Tumors · Colorectal Cancer · Gastric Cancer · Sponsor: Chimeric Therapeutics
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
This description comes directly from the study's public registry record.
Chimeric Clinical · (323) 366-9009 · clinical@chimerictherapeutics.com
Always discuss trial participation with your own doctor first.
| Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06055439